预约演示
更新于：2026-02-27
Nefopam Hydrochloride
盐酸奈福泮
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1985-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20ClNO |
InChIKeyCNNVSINJDJNHQK-UHFFFAOYSA-N |
CAS号23327-57-3 |
关联
113
项与 盐酸奈福泮 相关的临床试验NCT07423650
Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy: A Randomized Controlled Double-Blind Trial
KCT0011490
The effect of perioperative nefopam administration on postoperative depressive mood
TCTR20251224005
Can a Single Pre-incisional Dose Make a Difference? Analgesic Efficacy of Intravenous Nefopam in Unilateral Total Knee Arthroplasty: A Prospective Triple-Blind Randomized Controlled Trial
100 项与 盐酸奈福泮 相关的临床结果
登录后查看更多信息
100 项与 盐酸奈福泮 相关的转化医学
登录后查看更多信息
100 项与 盐酸奈福泮 相关的专利（医药）
登录后查看更多信息
647
项与 盐酸奈福泮 相关的文献（医药）2026-04-01Anaesthesia Critical Care & Pain Medicine
Comfort-Focused Assessment and Patient-Reported Experience After Regional versus General Anaesthesia: Post Hoc Analysis of a Cluster-Randomised Trial
Article
作者: Auquier, Pascal ; Rozier, Romain ; Meuret, Ludovic ; Beloeil, Hélène ; Fusco, Nicolas ; Loundou, Anderson ; Maurice-Szamburski, Axel
INTRODUCTION:
Postoperative pain management typically relies on numerical (NRS) or analogue rating scales. However, exclusive focus on nociception may overlook broader aspects of patient experience, especially under regional anaesthesia (RA). This post hoc analysis of the COMFORT trial (NCT05234216) examined whether replacing the NRS with a comfort-focused scale affects patient-reported experience, opioid use, and related outcomes.
METHODS:
We analysed data from a cluster-randomised trial in 29 French centres. Adults undergoing elective non-cardiac surgery managed in the post-anaesthesia care unit (PACU) were included. The intervention (comfort scale) and comparator (pain NRS) were applied in the PACU. Patient-reported experience was measured with the EVAN-G/LR scales, self-completed on the ward/day-care unit ≥4 h postoperatively. Participants were divided into RA and general anaesthesia subgroups.
RESULTS:
Of 885 randomised patients, 786 had evaluable EVAN data. After regional anaesthesia (RA; n = 305), comfort‑focused assessment was associated with higher EVAN Pain (median 88 [IQR 75-94] vs. 75 [69-88]; p = 0.034), Waiting (100 [75-100] vs. 75 [50-100]; p = 0.012), and Global Index (81 [72-91] vs. 77 [68-90]; p = 0.044). After general anaesthesia (GA; n = 481), EVAN scores were similar between groups. Nefopam use was lower with the comfort approach in RA (7% vs. 18%; p = 0.005). Antiemetic use was lower with the comfort approach in GA.
CONCLUSION:
Replacing the NRS with a comfort-focused approach did not improve global patient experience after surgery. In patients receiving regional anaesthesia, however, using a comfort scale was associated with better patient-reported experience in the EVAN "Pain" dimension, while no benefit was observed after general anaesthesia.
2025-11-01Anaesthesia Critical Care & Pain Medicine
The application of continuous nefopam infusion in analgesia and sedation for mechanically ventilated patients in the ICU: Authors' reply
Letter
作者: Mukhtar, Ahmed Mohammed ; Farid, Samar Farghali ; Sabry, Nirmeen Ahmed ; Abdelraouf, Mohammed Gamal
2025-10-01JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
Nefopam for Analgesia Following Cardiac Surgery: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Article
作者: Taechawattananan, Nalinpat ; Raykateeraroj, Nattaya ; Lertkovit, Saranya ; Kitisin, Nuanprae ; Saraphang, Saifon ; Vacharaksa, Kamheang ; Kongkanond, Tipkanya ; Subtaweesin, Thaworn ; Weinberg, Laurence
OBJECTIVE:
To evaluate the analgesic efficacy, opioid-sparing effects, and safety profile of nefopam compared with placebo following elective cardiac surgery.
DESIGN:
Randomized, double-blind, placebo-controlled trial at a tertiary care center.
SETTING:
Perioperative care.
PARTICIPANTS:
A total of 103 adults (mean age, 57.9 ± 11.3 years) undergoing elective cardiac surgery via median sternotomy were randomized to receive nefopam (n = 50) or placebo (n = 53).
INTERVENTIONS:
Patients were randomized to receive nefopam (20 mg intravenous [IV] bolus, followed by an 80 mg continuous infusion over 24 hours) or placebo, with both groups receiving standardized IV fentanyl via patient-controlled analgesia.
MEASUREMENTS AND MAIN RESULTS:
The primary outcome was cumulative fentanyl consumption over 48 hours. Secondary outcomes included pain scores (NRS 0-10), intubation duration, intensive care unit (ICU)/hospital length of stay, and adverse events. Both fentanyl consumption and pain scores were assessed at 3, 6, 12, 24, and 48 hours postoperatively. The nefopam group consumed 25% less fentanyl over 48 hours (mean, 16.3 ± 1.6 µg/kg vs 21.9 ± 1.6 µg/kg; p = 0.014), with significant reductions from 6 hours to 48 hours. Pain scores were lower in the nefopam group at rest at 48 hours (p = 0.03) and during movement at 24 and 48 hours (p = 0.04 and 0.01), although overall pain remained mild. Adverse events (eg, sinus tachycardia, agitation/delirium) were comparable in the 2 groups. Duration of intubation and ICU/hospital length of stay did not differ between the 2 groups.
CONCLUSIONS:
Nefopam was well tolerated and associated with statistically significant but clinically modest reductions in fentanyl use and pain scores after cardiac surgery, supporting its role as a safe adjunct in multimodal analgesia.
100 项与 盐酸奈福泮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 韩国 | 2008-06-11 | |
| 术后疼痛 | 韩国 | 2008-06-11 | |
| 疼痛 | 中国 | 1985-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性疼痛 | 临床1期 | 澳大利亚 | 2024-08-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 32 | (FDC Nefopam Hydrochloride 30mg / Paracetamol 500mg) | 願鹹襯襯淵鹽齋艱鑰蓋(製鹽餘網獵艱膚鹽夢廠) = 簾齋積獵醖衊膚鏇獵餘 壓窪構鹹鏇夢壓糧構窪 (憲範築繭願膚糧鬱鏇觸, 38.283) 更多 | - | 2024-10-31 | |
(Nefopam Hydrochloride 30mg) | 願鹹襯襯淵鹽齋艱鑰蓋(製鹽餘網獵艱膚鹽夢廠) = 糧簾網餘艱顧夢廠鹽構 壓窪構鹹鏇夢壓糧構窪 (憲範築繭願膚糧鬱鏇觸, 40.071) 更多 | ||||||
临床3期 | 40 | 鹹積齋醖觸鏇構鬱襯衊(簾積膚顧簾憲築選齋簾) = 憲餘蓋顧廠齋積鑰願淵 網夢襯鏇鏇醖築窪窪築 (範鏇構蓋艱願獵網觸選 ) | - | 2020-01-01 | |||
Placebo | 鹹積齋醖觸鏇構鬱襯衊(簾積膚顧簾憲築選齋簾) = 艱鬱願願獵築襯壓淵蓋 網夢襯鏇鏇醖築窪窪築 (範鏇構蓋艱願獵網觸選 ) | ||||||
N/A | 42 | 範壓壓簾遞觸餘壓醖壓(襯獵醖廠壓衊鬱範鏇淵) = 廠窪範夢繭簾願觸餘憲 顧鑰衊鏇繭積淵範壓觸 (網艱鹹製衊淵窪窪遞鹽 ) | 积极 | 2016-02-01 | |||
Placebo | 範壓壓簾遞觸餘壓醖壓(襯獵醖廠壓衊鬱範鏇淵) = 構範衊獵遞願鏇窪觸鹽 顧鑰衊鏇繭積淵範壓觸 (網艱鹹製衊淵窪窪遞鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用